1 Introduction to the medicine prices and availability survey and training workshop Presentation template for adaptation and use in medicine prices and.

Slides:



Advertisements
Similar presentations
THE CHALLENGES & OPORTUNITIES OF ACCESS TO MEDICINES IN AFRICA Dr Pascoal MOCUMBI, orig Mozambique,High Representative EDCTP ABRASCO/WFPHA.
Advertisements

Abt Associates Inc. In collaboration with: I Aga Khan Foundation I BearingPoint I Bitrán y Asociados I BRAC University I Broad Branch Associates I Forum.
Saul Walker Policy and Research Division, DFID Jordan 4 December, 2007 Medicines Transparency Alliance (MeTA)
Introduction of the Annual Report 1. Workshop towards equitable and affordable medicine prices policy in Jordan Dead Sea, Jordan Dead Sea, Jordan 4–5.
Medicine Prices Matter to People and Insurance Companies Margaret Ewen Health Action International.
1 Paying the Price Margaret Ewen Health Action International Europe.
1 Policy options to address access to chronic disease medicines Dr. Richard Laing Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical.
August 27th Availability, Pricing and Affordability of Asthma Medicines Presentation for Meeting on Availability, Pricing and Affordability.
1 Medicines for Chronic Diseases: too costly, too scarce, too important to ignore Margaret Ewen Health Action International.
Medicines Prices and Methods of Financing in South-East Asia Indian Pharmacological Society 38 th Annual Conference, Chennai 29th December 2005 Dr K Weerasuriya,
Completing the Medicine Price Data Collection form Presentation template for adaptation and use in medicine prices and availability survey training workshop.
Strategies to Improve Efficiency in Medicine Procurement Towards equitable and affordable medicine prices policies in Jordan Workshop 4-5 Dec, 2007 Dr.
MEDICINES PRICES IN INDONESIA Ms. Selma Siahaan Center for Health Services and Technology R&D National Institute of Health R&D Indonesia 14 June 2006.
1 Data entry Presentation template for adaptation and use in medicine prices and availability survey training workshop for survey personnel Review all.
1 Medicine Availability, Prices and Affordability in West Bengal, India (2004) DALIA DEY CUTS & CDMU.
1 Medicine Prices, Availability and Affordability Margaret Ewen Health Action International.
Lebanon, 2004 Medicine price survey in Lebanon, 2004 undertaken by Dr Rita Karam, Ministry of Health Marg Ewen (on behalf of Dr Karam) WHO/HAI post-medicine.
Data collection procedures Presentation template for adaptation and use in medicine prices and availability survey training workshop for survey personnel.
Overview of the medicine prices and availability survey methodology Presentation template for adaptation and use in medicine prices and availability survey.
Syria,2004 Medicine price survey in Syria, 2004 undertaken by Pharmaceutical Studies Directorate, Ministry of Health Presentation by Razan Sallouta WHO/HAI.
A MEDICINE PRICES SURVEY IN CHINA Presentation by Dr Xiaoxia Hu Research by Dr Sun Qiang and Dr Xiaoxia Hu June, 2006.
Mohamed Izham Mohamed Ibrahim
August 27th Availability, Pricing and Affordability of Cardiovascular Medicines Draft report for comments Maaike S.M. van Mourik University.
The prices of medicines worldwide & how they are determined Margaret Ewen Health Action International Europe Co-ordinator WHO/HAI Project on Medicine Prices.
Measuring Medicine Prices and Availability – a new Methodology and few Indian Survey Results Dr. Anita Kotwani Department of Pharmacology Vallabhbhai Patel.
MDG Target 8.E gap analysis Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical Policies, World Health Organization 27 August 2008.
Price, availability and affordability of medicines international comparison of 29 surveys Presented by: Richard Laing World Health Organization, Geneva.
Essential Medicines & Pharmaceutical Policies DHS/EMRO WHO Perspective on Medicine Prices & Policies Meeting of Drug Board on Medicine Pricing Federal.
Understanding the Antimalarials Market in Uganda Rosette Mutambi, HEPS Uganda Martin Auton, Health Action International, The Netherlands ASTMH, December.
External Financing for Health Care: Takemi Working Group Recommendations to G8 Ravi P. Rannan-Eliya ECOSOC Annual Ministerial Review – Regional Ministerial.
1 MDG Target 8.E gap analysis Dr Hans Hogerzeil Director, Department of Essential Medicines and Pharmaceutical Policies, World Health Organization October.
Finding a Common Denominator
1  1 =.
17 Sample Markup Problems
Commonwealth Connector Pharmacy Benefits July 12, 2007.
Confidential and Proprietary Information © 2011 Express Scripts, Inc. All Rights Reserved 1 The State of New Mexico Prescription Drug Program 2013.
Number bonds to 10,
OECD World Forum “Statistics, Knowledge and Policy”, Palermo, November
World Health Organization
Differences in the availability of medicines used for chronic and acute conditions in developing countries Alexandra Cameron International Conference on.
Global impact of medicine shortages Lisa Hedman World Health Organization Department of Essential Medicines and Health Products Toronto, Canada June.
1 Medicine prices and availability, evidence for policy Technical Briefing Seminar, November 3 rd 2010 Alexandra Cameron, Department of Essential Medicines.
1. Health Policy Research Group Department of Pharmacology & Therapeutics, College of Medicine, University of Nigeria Enugu Campus 2. Department of Clinical.
Birgit Kerstens 1, Samia Saad 2, Wilbert Bannenberg 1,2 1 Health Research for Action (HERA), Belgium; 2 Medicines Transparency Alliance (MeTA) Pilot, United.
Amanullah Saif Cost Accountant, Drug Control Administration Government of Pakistan WHO/HAI Project on Medicine Prices & Availability Cost Plus Price Setting.
Paying the Price: The Affordability of Medicines Across the Commonwealth (and elsewhere) Margaret Ewen Health Action International.
+ Facts + Figures: Your Introduction to Meetings Data Presented By: Name Title Organization.
WHO Level II Facility Surveys Douglas Ball Independent consultant, UK.
Cost as a Barrier to Access: Identifying the Component Costs of Essential Medicines Levison L,Laing RL.
1 Availability, price and affordability of cardiovascular medicines Richard Laing for Alexandra Cameron & Maaike van Mourik International Conference.
Medicines Transparency Alliance01/10/2015 Availability of Medicines Anita Wagner Harvard Medical School & WHO Collaborating Center in Pharmaceutical Policy.
1 Medicine prices and availability, evidence for policy Technical Briefing Seminar, November 18 th 2009 Alexandra Cameron, Department of Essential Medicines.
Summary of ICIUM Chronic Care Track Prepared by: Ricardo Perez-Cuevas Veronika Wirtz David Beran.
ASSESSMENT OF AVAILABILITY, PRICE AND AFFORDABILITY OF MEDICINES FOR CHILDREN IN GHANA Authors: Gyansa-Lutterodt M. 1,Andrews Annan E. 2, Koduah A. 1,
Medicines prices: measurement and findings in countries Richard Laing PSM - WHO Gilles Forte TCM - WHO Margaret Ewen HAI - Europe.
Margarit MELIKYAN Drug Utilization Research Group PO, Armenia, National Institute of Health Access to and Use of Medicines by Households in Armenia: Impact.
Pharmaceutical system strengthening – Is there a need for a new paradigm? Andreas Seiter The World Bank ICIUM 2011, Antalya 1.
Washington D.C., USA, July 2012www.aids2012.org Why do we need patent landscapes and what tools can be made available? Presenting the UNDP Patent.
Medicine Prices, Availability, Affordability and Price Components in Kazakhstan, Kyrgystan, Tajikistan & Uzbekistan Margaret Ewen Health Action International.
WHO-Health Action International project on drug price comparisons A technical project of the WHO-Public interest NGO round table on access to medicines.
Medicines Transparency Alliance - Zambia Billy Mweetwa Country Medicines Advisor – Zambia.
Medicines Transparency Alliance31/10/ MeTA Zambia – Pricing Goodwell Lungu MeTA Secretary General.
Objective the aim of this project was directly addressing a major health problem for Jordan by producing a guideline as a pilot in which the strengths.
Paying the price: Medicine prices, availability and affordability across the globe Alexandra Cameron Department of Essential Medicines and Pharmaceutical.
Out-of-pocket and Out-of-reach Margaret Ewen, Coordinator, Global Projects (Pricing) Health Action International Amsterdam.
MONITORING MEDICINE AVAILABILITY AND PRICES IN UGANDA By Denis Kibira HEPS Uganda.
1 Medicine prices and availability, evidence for policy Technical Briefing Seminar, 2012 Richard Laing with materials provided by Alexandra Cameron, Department.
WHO/Health Action International Project on Medicine Prices Margaret Ewen, HAI Europe Background and purpose of the project Technical approach to measuring.
Medicine prices and availability, evidence for policy
Presentation transcript:

1 Introduction to the medicine prices and availability survey and training workshop Presentation template for adaptation and use in medicine prices and availability survey training workshop for survey personnel Review all slides carefully for applicability to your survey before use! Medicine prices and availability survey Training workshop Location, dates

2 Why measure medicine prices and availability? Some facts and figures 1/3 of the world population lacks access to essential medicines (WHO, 2002) Improving access to medicines and vaccines could save approximately 10 million lives per year, 4 million in Africa and South-East Asia (DFID, 2004). Up to 90% of the population in developing countries must buy medicines through out-of-pocket payments (OECD 2005), making medicines the largest family expenditure after food Medicines account for 20-60% of health spending in developing and transitional countries (WHO, 2004) - a major burden on government budgets

3 Objectives of the medicine prices and availability survey To generate reliable information on the price, availability and affordability of selected important medicines, and price components in the supply chain, towards the ultimate goal of improving access to affordable medicines for all. NOTE TO SURVEY MANAGER: COMPLETE WITH YOUR SURVEY'S SPECIFIC OBJECTIVES

4 Questions that will be answered by the survey: What prices do people pay for key medicines? Does the price & availability of the same medicines vary across different sectors or regions of the country? What is the difference in price and availability of originator brands and lowest price generic equivalents? How do government procurement prices compare with patient prices in the public sector? How do national prices compare with international reference prices? How affordable are treatments for low paid people? What does the manufacturers price, taxes, mark-ups and other charges contribute to the final patient price?

5 How the data generated by the survey will be used NOTE TO SURVEY MANAGER: COMPLETE AS APPROPRIATE FOR YOUR SURVEY (EG AS A BASELINE FOR MEASURING IMPACT OF POLICY CHANGE, TO SUPPORT AN ADVOCACY CAMPAIGN)

6 Developed by experts under the coordination of the World Health Organization and Health Action International Measures: patient prices public sector procurement prices availability treatment affordability price components in the supply chain More than 70 surveys to date Standard methodology for measuring medicine prices and availability The survey tool

7 Example of data generated from survey: Ratio of median local price to international reference prices, atenolol 50mg tab, private retail pharmacies

8 Public sectorPrivate sector OriginatorGenericOriginatorGeneric Chad (2004) 4%0%18%0% Maharashtra (2005) 0% 10% Mongolia (2004) 0% 4% Philippines (2002) 15%0%9%1% Indonesia (2004) 0% 2%0% Morocco (2004) 25%65%5%50% Example of data generated from survey: Availability: beclometasone inhaler 50mcg/dose

9 Example of data generated from survey: Affordability: fluoxetine 40mg tab/day 30 days treatment, private retail pharmacies 96 »

10 Why is data quality important? Solid data supports solid conclusions & recommendations Future public policy decisions may rely on this evidence Critics will look for weaknesses & holes Results will be publicly accessible Project values: honesty & transparency Fairness to affected parties

11 Training workshop for medicine prices and availability survey Objective: To provide you with the knowledge and skills required to carry out the medicine prices and availability survey in an accurate and reliable manner Duration: 3 days Format: presentations and exercises, and a data collection pilot test NOTE TO SURVEY MANAGER: ADD ANY LOGISTIC INFORMATION, E.G. START/END TIMES

12 Training agenda NOTE TO SURVEY MANAGER: COMPLETE WITH YOUR SURVEY'S AGENDA

13 Training workshop ground rules Your participation is the key to the success of the workshop The survey is complex; feel free to ask questions Listen to one and other respectfully We have a lot to cover - arrive on time for all sessions It's ok to have fun! NOTE TO SURVEY MANAGER: Add other ground rules as identified by participants